Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

Source: Key Decisions in HIV Care
Listen as William R. Short, MD, MPH, AAHIVS, discusses the data to help you determine when switching to 2-drug single-tablet regimens may be warranted.
William R. Short, MD, MPH, AAHIVS
Released: November 10, 2021

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.

Listen as he gives his perspectives on:

  • Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
  • The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
  • Real-world experience with switching to DTG/RPV from the OPERA study
  • The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
  • The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this podcast from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: February 1, 2023

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: January 20, 2023 Expired: January 19, 2024
Introduction
Patient Candidacy
Administering LA ART
Clinic Infrastructure
What the Future Holds
Q&A Session

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings